Healthcare OEMs and fabricators are constantly looking for advanced and versatile material technologies to address increasing medical expenses, rising demand for both complicated and disposable medical devices, and the requirements of rigorous healthcare standards. Dow Corning says that these converging trends are the growth drivers for its extensive range of high-performance liquid silicone rubber (LSR) solutions.
The LSR solutions offered by Dow Corning include Dow Corning® QP1 LSR product line, Dow Corning® Class VI C6 LSRs, biomedical-grade Silastic® LSRs, and Dow Corning® QP1-2XX LSR family. The company plans to introduce the Dow Corning® QP1-2XX LSR line in early 2015. In the medical industry, LSRs are gaining traction as they can be easily processed and formed into high-precision components. Improved durability is the added advantage of Dow Corning’s QP1 LSRs, making them suitable for challenging applications.
The improved rheology offered by Dow Corning’s new QP1-2XX product family allows rapid flow at low pressures, thereby facilitating high-volume liquid injection molding of tiny and intricate medical components at a lower cost. Moreover, with a fast cure profile, Dow Corning’s advanced LSRs shorten cycle times by roughly 15% when compared to competitive silicone materials.
The versatility and outstanding performance of our industry-leading LSR portfolio uniquely illustrates Dow Corning’s six decades of customer collaboration and materials innovation within the health care market.
Gary Lord, global strategic marketing director for Healthcare at Dow Corning
All LSR products in existing QP1 and planned QP1-2XX product families offered by Dow Corning are silicone elastomers manufactured using platinum catalysts, as outlined by the ISO 9001 standard. In addition, Dow Corning’s production facilities are regularly audited in order to fulfill the prerequisites of rigorous healthcare regulations.